Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma

Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine

(2021) Florian Krammer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Low Neutralizing Antibody Responses Against SARS-CoV-2 in Elderly Myeloma Patients After the First BNT162b2 Vaccine Dose

(2021) Evangelos Terpos et al.   BLOOD

Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution

(2021) Fulvia Pimpinelli et al.   Journal of Hematology & Oncology

Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study

(2021) Leticia Monin et al.   LANCET ONCOLOGY

Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2

(2021) Joseph E. Ebinger et al.   NATURE MEDICINE

Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma

(2021) Sarah Bird et al.   Lancet Haematology

Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series

(2021) William A. Werbel et al.   ANNALS OF INTERNAL MEDICINE

Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer

(2021) Alfredo Addeo et al.   CANCER CELL

Seroconversion rates following COVID-19 vaccination among patients with cancer

(2021) Astha Thakkar et al.   CANCER CELL

A serological assay to detect SARS-CoV-2 seroconversion in humans

(2020) Fatima Amanat et al.   NATURE MEDICINE